T3	Treatment 0 116	Administration of intrathecal Ara-C in the same dose over longer intervals within 3-5 days between consecutive doses
T5	Effect 145 166	neurological symptoms
T6	Subject 190 208	one of 30 patients
T7	Population 190 199	one of 30
T8	Route 18 29	intrathecal
T9	Drug 30 35	Ara-C
T10	Freq 58 116	longer intervals within 3-5 days between consecutive doses
T11	Severity_cue 129 133	mild
T4	Adverse_event 117 125	resulted
E1	Adverse_event:T4 
A1	Severity E1 Low